News
SDZNY
82.61
+0.68%
0.56
Sandoz appoints Armin Metzger as President of Biosimilar Development, Manufacturing & Supply
Reuters · 52m ago
Sandoz Group Earnings Call Highlights Biosimilar-Fueled Surge
TipRanks · 6h ago
Weekly Report: what happened at SDZNY last week (0302-0306)?
Weekly Report · 21h ago
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
NASDAQ · 4d ago
Berenberg Bank Sticks to Their Hold Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 5d ago
3 Generic Drug Stocks to Watch Despite Industry Headwinds
NASDAQ · 5d ago
Weekly Report: what happened at SDZNY last week (0223-0227)?
Weekly Report · 03/02 09:48
Sandoz downgraded to Hold from Buy at Deutsche Bank
TipRanks · 02/26 22:35
Sandoz downgraded to Equal Weight from Overweight at Barclays
TipRanks · 02/26 09:35
Barclays downgrades Sandoz Group Ltd (SDZXF) to a Hold
TipRanks · 02/26 07:25
Sandoz Group AG Non-GAAP EPS of $3.64 beats by $0.38, revenue of $11.1B beats by $20M
Seeking Alpha · 02/25 13:41
Sandoz Group AG Publishes Transcript of FY 2025 Results Analyst Call
Reuters · 02/25 06:06
Sandoz confirms E.C. granted marketing authorization for Ranluspec
TipRanks · 02/23 11:38
European Commission approves Sandoz Ranluspec ranibizumab biosimilar
Reuters · 02/23 10:00
Weekly Report: what happened at SDZNY last week (0216-0220)?
Weekly Report · 02/23 09:48
Jefferies Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 02/20 15:35
Kepler Capital Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 02/20 01:48
Sandoz receives U.S. FDA approval to expand Enzeevu label
TipRanks · 02/18 11:55
Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
Seeking Alpha · 02/18 10:09
Sandoz joins new multi-buyer renewable electricity agreements in Europe
Reuters · 02/18 07:12
More
Webull provides a variety of real-time SDZNY stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZNY
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.